Ascendis Pharma price target raised to $275 from $250 at RBC Capital

RBC Capital raised the firm’s price target on Ascendis Pharma (ASND) to $275 from $250 and keeps an Outperform rating on the shares. The firm cites the FDA having approved Yuviwel for achondroplasia in patients 2 years of age and older as well as having granted the company a PRV – Priority Review Voucher. RBC continues to like the set-up on Ascendis given its “extensive checks” suggesting that Yorvipath will likely be a multi-billion dollar drug, the analyst tells investors in a research note.